CD8A and cancer: To address if the dual treatment could activate the systemic tumour-specific cellular immunity, we isolated splenic CD8+ T cells from the tumour-bearing mice receiving different treatments and re-stimulated with mitomycin C-treated MC38-luc or control B16 cancer cells in the presence of irradiated CD8-depleted splenocytes from naive B6 mice in vitro for 48 h.